CAMP4 Therapeutics (NASDAQ:CAMP) Director Andrew Schwab Sells 114,700 Shares of Stock

Key Points

• Director Andrew Schwab sold 114,700 CAMP4 Therapeutics shares at an average price of $4.54, generating approximately $520,738. He retained 2,465,298 shares, a 4.45% reduction in ownership.
• CAMP shares rose 0.4% to $4.48, but the company reported a quarterly loss of $0.58 per share, missing analyst expectations of a $0.24 loss; quarterly revenue was $1.78 million.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $9.56, while several institutional investors recently established new positions.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) Director Andrew Schwab sold 114,700 shares of CAMP4 Therapeutics stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $4.54, for a total value of $520,738.00. Following the completion of the transaction, the director owned 2,465,298 shares in the company, valued at $11,192,452.92. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

CAMP4 Therapeutics Trading Up 0.4%

Shares of CAMP traded up $0.02 during trading hours on Friday, hitting $4.48. The company had a trading volume of 126,663 shares, compared to its average volume of 183,971. The company has a market capitalization of $281.12 million, a PE ratio of -1.93 and a beta of 0.22. CAMP4 Therapeutics Corporation has a one year low of $1.41 and a one year high of $7.75. The company's fifty day moving average price is $4.11 and its two-hundred day moving average price is $4.33.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). The company had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. Analysts forecast that CAMP4 Therapeutics Corporation will post -0.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CAMP. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Piper Sandler reissued an "overweight" rating and set a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the stock a "buy" rating in a report on Wednesday, June 10th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Finally, Weiss Ratings upgraded CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, August 14th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $9.56.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bridgeway Capital Management LLC purchased a new stake in shares of CAMP4 Therapeutics during the second quarter valued at $36,000. China Universal Asset Management Co. Ltd. purchased a new position in CAMP4 Therapeutics in the 4th quarter worth $61,000. Jefferies Financial Group Inc. acquired a new stake in CAMP4 Therapeutics during the 4th quarter worth about $70,000. Bank of America Corp DE acquired a new stake in CAMP4 Therapeutics during the 2nd quarter worth about $78,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in CAMP4 Therapeutics during the 4th quarter valued at about $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source